Vaxcyte, Inc. (NASDAQ:PCVX) Given Average Recommendation of "Buy" by Brokerages

Shares of Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) have been assigned a consensus recommendation of "Buy" from the ten research firms that are currently covering the stock, Marketbeat.com reports. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $136.50.

PCVX has been the subject of several analyst reports. Needham & Company LLC reiterated a "buy" rating and issued a $90.00 price objective on shares of Vaxcyte in a research report on Tuesday, April 8th. Bank of America lowered their price objective on Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. The Goldman Sachs Group lowered their price target on Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Evercore ISI upgraded Vaxcyte to a "strong-buy" rating in a research report on Monday, March 31st. Finally, Cantor Fitzgerald assumed coverage on Vaxcyte in a research report on Tuesday, April 22nd. They set an "overweight" rating for the company.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Bridgefront Capital LLC boosted its holdings in Vaxcyte by 4.2% in the fourth quarter. Bridgefront Capital LLC now owns 4,244 shares of the company's stock valued at $347,000 after purchasing an additional 172 shares during the period. Nisa Investment Advisors LLC raised its stake in Vaxcyte by 10.9% in the first quarter. Nisa Investment Advisors LLC now owns 2,977 shares of the company's stock valued at $112,000 after buying an additional 293 shares in the last quarter. Avior Wealth Management LLC raised its stake in Vaxcyte by 5.3% in the first quarter. Avior Wealth Management LLC now owns 6,799 shares of the company's stock valued at $257,000 after buying an additional 343 shares in the last quarter. US Bancorp DE raised its stake in Vaxcyte by 7.2% in the first quarter. US Bancorp DE now owns 5,344 shares of the company's stock valued at $202,000 after buying an additional 357 shares in the last quarter. Finally, Xponance Inc. raised its stake in Vaxcyte by 4.7% in the first quarter. Xponance Inc. now owns 9,320 shares of the company's stock valued at $352,000 after buying an additional 415 shares in the last quarter. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Vaxcyte Trading Up 1.1%

Vaxcyte stock traded up $0.39 during mid-day trading on Friday, hitting $36.63. The company's stock had a trading volume of 1,088,735 shares, compared to its average volume of 1,427,526. The firm has a market capitalization of $4.73 billion, a PE ratio of -9.18 and a beta of 1.19. Vaxcyte has a 1 year low of $27.66 and a 1 year high of $121.06. The stock's fifty day moving average is $34.38 and its two-hundred day moving average is $52.17.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same period in the prior year, the firm posted ($0.85) earnings per share. On average, equities analysts expect that Vaxcyte will post -4.21 EPS for the current fiscal year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.